- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03622931
Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines (TRACEII)
February 3, 2021 updated by: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Double-blind, Placebo-controlled Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Subjects With Relapsed Ovarian Cancer (2nd or Further Line)
To evaluate the safety of secondary chemotherapy induced thrombocytopenia (reduction in platelets which leads to bleeding) prophylaxis with romiplostim in ovarian cancer subjects receiving myelosuppressive (blood cell damaging) chemotherapy.It is anticipated that Romiplostim, when administered at an effective dose and schedule, will be a well-tolerated treatment for subjects experiencing chemotherapy-induced thrombocytopenia.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Chemotherapy of recurrent ovarian cancer leads to severe thrombocytopenia in a considerable proportion of the patients, requiring treatment delays or dose reductions, and placing the patient at a high risk of bleeding complications.
The amount of thrombocytopenia is highly schedule-dependent.
In platinum-sensitive ovarian cancer that relapsed more than 6 months after end of primary therapy, a platinum containing reinduction therapy - the combination of paclitaxel/carboplatin, gemcitabine/carboplatin or PLD/carboplatin - is recommended according to the current AGO guidelines or recent ASCO presentations.
Especially the latter two regimens often induce severe and even dose-limiting myelosuppression, including thrombocytopenia.
Therefore, prophylaxis, or at least secondary prophylaxis of this toxicity is an important goal of supportive therapy.
The use of platelet transfusions is limited by cost, supply problems, and associated risks, such as transfusion reactions, transmission of infection, and alloimmunization and platelet refractoriness.
In contrast to the situation for the red and white blood cell compartments, the implementation of growth factor treatment in order to ameliorate the therapy of thrombocytopenia and its complications, is yet very limited.
Romiplostim is an active second-generation thrombopoietic agent without safety problems due to immunogenicity, which proved to be beneficial in the treatment of immune thrombocytopenic purpura and myelodysplastic syndromes.
The rationale of this trial is to obtain evidence that romiplostim can improve platelet counts/recovery in the treatment of recurrent ovarian cancer.
Due to the fact, that the expected occurrence of severe thrombocytopenia and its complications may heavily depend on the selection of patient and their characteristics such as actually chosen treatment schedule, tumor stage, extent of metastasis, pre-treatment etc. a phase II design comparing the results to historical data or expectations is insufficient.
A simple within-group control design, comparing subsequent cycles of the same patients with or without the supportive experimental drug may also be flawed, as "spontaneous" improvements after obviously unchanged chemotherapy are often observed.
With some regimens, the first cycle proves to be generally more toxic than later ones.
On the other hand, regimens may result in cumulative myelosuppression.
A design including a randomized doubleblind control group is therefore warranted, moreover, as platelet counts represent a sensitive and valid surrogate marker for a clinical benefit.
The current study will employ a model of secondary prophylaxis.
The enrolment of subjects with grade 3 and/or 4 thrombocytopenia will facilitate an assessment of the ability of romiplostim to impact thrombocytopenia at clinically significant levels, which warrant the administration of platelet transfusions, dose reduction, and dose delay.
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 10367
- Praxisklinik für Krebsheilkunde für Frauen Drs. Kittel /Klare / Wetzel
-
Berlin, Germany, 13353
- Charité Campus Virchow-Klinikum Universitätsmedizin Berlin
-
Berlin, Germany, 13589
- Ev. Waldkrankenhaus Spandau
-
Bonn, Germany, 53111
- Gynäkologisches Zentrum
-
Brandenburg, Germany, 14770
- Städtisches Klinikum Brandenburg
-
Braunschweig, Germany, 38100
- Gemeinschaftspraxis Dr. Lorenz, Hecker, Wesche
-
Chemnitz, Germany, 09116
- Klinikum Chemnitz GmbH
-
Dresden, Germany, 01307
- Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden
-
Jena, Germany, 07743
- Universitätsklinikum Jena
-
Kiel, Germany, 24105
- Universitätsklinikum Schleswig-Holstein Campus Kiel
-
Mainz, Germany, 55131
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz
-
Saarbrücken, Germany, 66113
- Caritasklinik St. Theresia Saarbrücken
-
Tübingen, Germany
- Universitätsklinikum Tübingen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women ≥ 18 years of age
- Before any study-specific procedure, the appropriate written informed consent must be obtained, according to ICH-GCP, and national/local regulation
- ANC ≥ 1,000/μl, Hgb ≥ 9.5 g/dl, and platelet count ≥ 100 x 109/l on day 1 of the first on study cycle of the chemotherapy treatment (on-study cycle) (Thrombocytopenia have to be defined during a "qualifying cycle"; qualifying cycle could be the 1st or the 2nd cycle of the palliative chemotherapy; thrombocytopenia as evidenced by a platelet count < 50 x 109/l during the qualifying cycle of chemotherapy OR platelet count < 100 x 109/l on the planned starting day of the next cycle of chemotherapy (or 1-3 days before), requiring dose delay for platelet recovery.)
Subjects with histologically confirmed advanced or metastatic ovarian cancer, fallopian tube cancer, peritoneal carcinoma or ovarian carcinosarcoma who are receiving 2nd or further line chemotherapy consisting of one of the following regimens according to established dosing standards:
- Topotecan, d 1-5, q3w
- Gemcitabine, d1+8, q3w
- Carboplatin / paclitaxel, d1, q3w
- Carboplatin d1 /gemcitabine, d1+d8, q3w
- Carboplatin / pegylated liposomal doxorubicin, d1, q4w
- Carboplatin d1 / gemcitabine, d1+d8, Avastin d1, q3w
- Topotecan d1-5 + avastin, q3w
- Carboplatin + paclitaxel + avastin, q3w
- Thrombocytopenia as evidenced by a platelet count < 50 x 109/l during the qualifying cycle of chemotherapy OR platelet count < 100 x 109/l on the planned starting day of the next cycle of chemotherapy (or 1-3 days before), requiring dose delay for platelet recovery; qualifying cycle could be the 1st or the 2nd cycle of chemotherapy
- Life expectancy ≥ 12 weeks at the time of screening
- Ability to receive the same dose and schedule of chemotherapy during the first on study treatment cycle as was given in the qualifying cycle(s). (In case of grade 4 thrombocytopenia: a dose reduction to ≥75% of the previous dose schedule is allowed.)
Exclusion Criteria:
- Previous treatment with PEG-rHuMGDF, recombinant human thrombopoietin (rHuTPO), romiplostim, eltrombopag, or another thrombopoietic protein
- Past or current history of malignancies that affect the overall prognosis (Please note: patients with past or current malignancies not affecting the overall prognosis are allowed for enrollment)
- Subjects, who have had a larger surgery within the last 2 weeks before entering this study
- Active participation in any other clinical study
- Subjects with an active infection; sepsis, disseminated intravascular coagulation, or any other condition (i.e. myelodysplastic syndrome {MDS}, immune thrombocytopenic purpura {ITP}, thrombotic thrombocytopenic purpura {TTP}, hemolytic uremic syndrome {HUS}) that may have exacerbated thrombocytopenia
- History of unstable angina, CHF {NYHA >class II}, uncontrolled hypertension {diastolic >100mm HG}, uncontrolled cardiac arrhythmia, or recent (within 1 year of screening) myocardial infarction (MI)
- History of arterial thrombosis (e.g., stroke or transient ischemic attack) within 1 year of screening
- History of pulmonary embolism or other venous thrombosis within 1 year of screening (except for catheter-related clots)
- Receipt of any experimental therapy within the last 4 weeks prior to screening; subject is currently enrolled in, or has completed within the last 30 days, another investigational device or drug study (exception: PROVE study)
- Receipt of a bone marrow or peripheral blood stem cell infusion (within 1 year of screening)
- Positive Pregnancy test
- breast feeding period
- Reproductive potential and not using adequate highly effective methods of contraceptive precautions in the judgment of the investigator during treatment and for 6 month (male or female) after the end of treatment (adequate: oral contraceptives, intrauterine device or barrier method in conjunction with spermicidial jelly)
- Known hypersensitivity to any recombinant E. Coli-derived product or any additives
- Inability to comply with the protocol or missing written informed consent
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.
- Accommodation in an institution due to official or legal orders (§40 p.1 No. 4 AMG)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: the experimental arm
standard chemotherapy at 3/4-weekly intervals (cf.
inclusion criteria) + romiplostim 750 μg sc once per week for up to 4 cycles
|
Chemotherapy
|
Placebo Comparator: the placebo arm
standard chemotherapy at 3/4-weekly intervals (cf.
inclusion criteria) + placebo once per week for up to 4 cycles
|
Chemotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Grade 3 and 4 thrombocytopenia
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
Platelet Count (100 x 10^9/L) will be measured and the rate will be compared by Treatment Group
|
At the end of Cycle 1 (each cycle is 28 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events of grade 3/4
Time Frame: At the end of Cycle 4 (each cycle is 28 days)
|
Determine the rate of AE between the experimental arm and the placebo arm.
|
At the end of Cycle 4 (each cycle is 28 days)
|
Grade 3/4 thrombocytopenia
Time Frame: on days 8, 11 or 12, 15
|
The rate of AE between the experimental arm and the placebo arm will be determined
|
on days 8, 11 or 12, 15
|
Platelet Counts
Time Frame: on days 8, 11 or 12, 15
|
The average platelet nadir in each treatment Group will be considered
|
on days 8, 11 or 12, 15
|
Bleeding events
Time Frame: At the end of Cycle 8 (each cycle is 28 days)
|
The proportion of patients suffering from grade 1, 2, 3, or 4 bleeding Events will be considered
|
At the end of Cycle 8 (each cycle is 28 days)
|
Grade 1, 2, 3, or 4 thrombocytopenia (maximum NCI CTC grade by patient)
Time Frame: At the end of Cycle 8 (each cycle is 28 days)
|
Determine the proportion of subjects in each treatment group
|
At the end of Cycle 8 (each cycle is 28 days)
|
Grade 3/4 thrombocytopenia
Time Frame: At the end of Cycle 8 (each cycle is 28 days)
|
The duration will be considered
|
At the end of Cycle 8 (each cycle is 28 days)
|
Platelet transfusions
Time Frame: At the end of Cycle 8 (each cycle is 28 days)
|
The number of subjects in each treatment Group will be considered
|
At the end of Cycle 8 (each cycle is 28 days)
|
Platelet counts
Time Frame: On day 22 of each Cycle till max. 8 Cycles (each cycle is 28 days)
|
The platelet counts on study chemotherapy treatment cycles by treatment group will be considered.
|
On day 22 of each Cycle till max. 8 Cycles (each cycle is 28 days)
|
Counts of CT cycles
Time Frame: through study completion, an average of 8 month
|
The proportion of subjects able to receive all CT cycles on time by treatment group
|
through study completion, an average of 8 month
|
ADR/SADR of romiplostim
Time Frame: through study completion, an average of 8 month
|
Assess the reported ADR/SADR
|
through study completion, an average of 8 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jalid Sehouli, Prof. Dr. med., Frauenklinik
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2014
Primary Completion (Actual)
January 1, 2019
Study Completion (Actual)
January 17, 2019
Study Registration Dates
First Submitted
January 18, 2018
First Submitted That Met QC Criteria
August 8, 2018
First Posted (Actual)
August 9, 2018
Study Record Updates
Last Update Posted (Actual)
February 8, 2021
Last Update Submitted That Met QC Criteria
February 3, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
- T-RACE II
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Cancer
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Eve RodlerNot yet recruitingBreast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
University of WashingtonMinnesota Ovarian Cancer AllianceTerminatedStage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IVA Ovarian Cancer AJCC v8 | Stage IVB Ovarian... and other conditionsUnited States
Clinical Trials on Placebos
-
Yiling Pharmaceutical Inc.Completed
-
Nova Scotia Health AuthorityRecruiting
-
Beth Israel Deaconess Medical CenterTerminated
-
Intra-Cellular Therapies, Inc.CompletedBipolar Depression | Major Depressive DisorderUnited States, Bulgaria, Russian Federation, Serbia, Ukraine
-
Josef Smolen, Univ. Prof. Dr.Unknown
-
GE HealthcareSyneos HealthTerminatedChronic Kidney DiseasesUnited States, Spain, Belgium, Canada, Poland, United Kingdom
-
Viela BioCTI Clinical Trial and Consulting ServicesTerminated
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Completed
-
Viking Therapeutics, Inc.Active, not recruitingNASH - Nonalcoholic SteatohepatitisUnited States, Belgium, France, Mexico, Puerto Rico
-
Shengjing HospitalEnrolling by invitation